Synovetin OA
A conversation with Dr. Robert Menardi, DVM and Chief Medical Officer at Exubrion Therapeutics
Canine osteoarthritis (OA) is a disease of rampant inflammation that causes pain and debilitation.1
Medications designed to block pain signals cannot effectively address the inflammation that is damaging the joint, which allows the vicious cycle of inflammation and cartilage deterioration to continue.2
But Synovetin OA® targets canine OA at its source – the inflammation. It is injected directly into the joint where it works to safely deactivate the inflammatory cells that drive cartilage destruction and pain.3-5
3-minute video:
Hear how Synovetin OA addresses both pain and inflammation.
Synovetin OA
Don’t miss this video discussion about how the unique benefits of Synovetin OA are answering a critical unmet need in canine OA treatment.
Topics covered include:
- How Synovetin OA works within the joint to address the inflammation that leads to pain, progressive joint destruction, and debilitation
- Clinical evidence from published, peer reviewed studies and experience in clinical practice
- Demonstrated safety with no systemic side effects
- Guidance on when Synovetin OA should be considered
References: 1. Sokolove J, Lepus CM. Ther Adv Musculoskel Dis. 2013;5(2):77-94. 2. ACVS. Canine Elbow Dysplasia. Available at: https://www.acvs.org/small-animal/canine-elbow-dysplasia. Accessed April 7, 2025. 3. Aulakh KS, Lopez MJ, Hudson C, et al. Vet Med (Auckl). 2021;12:117-128. doi: 10.2147/VMRR.S295309. PMID: 34113552; PMCID: PMC8187093. 4. Donecker J, Fabiani M, Gaschen L, Aulakh KS. PLoS One. 2021;16(7):e0254613. doi: 10.1371/journal.pone.0254613. PMID: 34280212; PMCID: PMC8289027. 5. Donecker J, Lattimer JC, Gaschen L, Aulakh KS. Vet Med (Auckl). 2021;12:325-335. doi: 10.2147/VMRR.S345144. PMID: 34950571; PMCID: PMC8691448.